

**The listing of claims presented below replaces all prior versions and listing of claims in the application.**

**Listing of claims:**

1. (Withdrawn) A method for the treatment of an individual having a condition characterized by abnormal myocardial cell  $\text{Na}^+$ ,  $\text{K}^+$  or  $\text{Ca}^{2+}$  ion levels, said method comprising administering a therapeutically effective amount of one or more ~~ss-~~  $\beta_3$  adrenoceptor agonists to said individual.
2. (Withdrawn) The method according to claim 1 wherein the condition is selected from the group consisting of heart failure, and myocardial hypertrophy.
3. (Currently amended) A method for the treatment of a human suffering from ~~or susceptible to chronic symptomatic heart failure with impaired systolic left ventricular function or myocardial hypertrophy~~, said method comprising administering a therapeutically effective amount of one or more  $\beta_3$  adrenoceptor agonists to said human .
4. (Canceled).
5. (Previously presented) The method according to claim 3 wherein the  $\beta_3$ - adrenoceptor agonist is selected from the group consisting of arylethanolamines, aryloxypropanolamines, and trimetoquinols.
6. (Previously presented) The method according to claim 3 wherein the  $\beta_3$  adrenoceptor agonist is selected from the group consisting of BRL37344, BRL 26830, BRL 26830A, BRL 35113, ZD7114, CGP12177, CGP 12177A, CGP-20712A, CL316243, ICI07114, ICI215001, ICI 201651, BRL35135A, BRL28410, N-5984, (R)-N-[4-[2-[[2-Hydroxy-2- (pyridin-3-yl)ethyl]amino]ethyl]phenyl]- 4- [4-(4-trifluoro-methylphenyl)thiazol-2- yl] benzenesulfonamide (L-796568), (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)-ethyl]amino]ethyl]phenyl]-1-(4-octylthiazol-2-yl)-5-indolinesulfonamide (L-755507), L-770,644, L-766,892, L-757,793, L-796568, LY-377604, Ro 40-2148, SB-220646, SB-

226552, SB-251023, SB-262552, SR 58306, SR 58375, SR 58339, SR 58611, SR 58611A, SR 59119A, GR-265261-X, AD-9677, and agonists of the series 2-(3-indolyl) alkylamino-1-(3-chlorophenyl)ethanols.

7. (Original) The method according to claim 3 wherein the  $\beta_3$  adrenoceptor agonist is BRL37344.

8. (Currently amended) The method according to claim 3 wherein the  $\beta_3$ -adrenoceptor  $\beta_3$ -adrenoceptor agonist further comprises  $\beta_1$  antagonist activity and/or further comprises  $\beta_2$  antagonist activity.

9. (Previously presented) The method according to claim 3 further comprising administering one or more  $\beta$  blockers to said human.

10. (Original) The method according to claim 9 wherein the  $\beta$  blocker is nadolol.

11. (Original) The method according to claim 9 wherein the  $\beta$  blocker is a  $\beta_1$  and/or  $\beta_2$  adrenoceptor antagonist.

12. (Previously presented) The method according to claim 9 wherein the  $\beta$  blocker is administered to said human prior to, simultaneously with or subsequent to administration of the one or more  $\beta_3$  adrenoceptor agonists.

13. (Previously presented) The method according to claim 3 wherein said human is suffering from chronic heart failure and further comprising at least partially stabilizing said human prior to administration of said  $\beta_3$  adrenoceptor agonist.

14. (Original) The method according to claim 13 wherein said stabilizing comprises treatment with one or more compounds selected from the group consisting of ACE-inhibitors, aldosterone antagonists and  $\beta$ -adrenoceptor antagonists.

15. (Withdrawn) A method for treatment of a condition characterized by abnormally high

myocardial cell Na<sup>+</sup> ion level, said method comprising administration to an individual having said condition of a therapeutically effective amount of one or more β<sub>3</sub>- adrenoceptor agonists.

16. (Withdrawn) The method according to claim 15 wherein said condition characterized by abnormally high myocardial cell Na<sup>+</sup> ion level is selected from the group consisting of heart failure, myocardial hypertrophy, and diabetic cardiomyopathy.

17. (Withdrawn) Use of one or more β<sub>3</sub> adrenoceptor agonists for the manufacture of a medicament for treatment of an individual having a condition characterized by abnormal myocardial cell Na<sup>+</sup>, K<sup>+</sup> or Ca<sup>2+</sup> ion levels.

18. (Withdrawn) One or more β<sub>3</sub>-adrenoceptor agonists for use in the treatment of an individual having a condition characterized by abnormal myocardial cell Na<sup>+</sup>, K<sup>+</sup> or Ca<sup>2+</sup> ion levels.

19. (Withdrawn) Use of one or more β<sub>3</sub>-adrenoceptor agonists for the manufacture of a medicament for treatment of an individual suffering from or susceptible to heart failure or myocardial hypertrophy.

20. (Withdrawn) One or more β<sub>3</sub>-adrenoceptor agonists for use in the treatment of an individual suffering from or susceptible to heart failure or myocardial hypertrophy.

21. (Withdrawn) A pharmaceutical composition for use in the treatment of an individual having a condition characterized by abnormal myocardial cell Na<sup>+</sup>, K<sup>+</sup> or Ca<sup>2+</sup> ion levels, the composition comprising one or more β<sub>3</sub> adrenoceptor agonists together with one or more pharmaceutically acceptable adjuvants, excipients and/or carriers.

22. (Withdrawn) A pharmaceutical composition for use in the treatment of an individual suffering from or susceptible to heart failure or myocardial hypertrophy, the composition comprising one or more β<sub>3</sub> adrenoceptor agonists together with one or more pharmaceutically acceptable adjuvants, excipients and/or carriers.

23. (Withdrawn) A pharmaceutical composition comprising one or more  $\beta_3$  adrenoceptor agonists and one or more  $\beta_1$  and/or  $\beta_2$  adrenoceptor antagonists, together with one or more pharmaceutically acceptable adjuvants, excipients and/or carriers.

24. (Withdrawn) A method for the extrusion of  $\text{Na}^+$  from a myocardial cell or cells, the method comprising contacting said cell (s) one or more  $\beta_3$  adrenoceptor agonist(s).

25. (Withdrawn) The method according to claim 24 wherein said method comprises  $\text{Na},\text{K}$  pump stimulation.